Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives $63.33 Consensus Target Price from Analysts

by · The Cerbat Gem

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Free Report) have earned an average recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued a report on the stock in the last year is $63.33.

ESTA has been the subject of a number of analyst reports. JPMorgan Chase & Co. upped their target price on Establishment Labs from $46.00 to $53.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. Mizuho increased their price objective on Establishment Labs from $50.00 to $65.00 and gave the company a “buy” rating in a report on Monday, April 1st. Citigroup increased their price objective on Establishment Labs from $49.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Finally, Stephens reiterated an “overweight” rating and set a $47.00 price objective on shares of Establishment Labs in a report on Thursday, January 11th.

Check Out Our Latest Stock Analysis on ESTA

Hedge Funds Weigh In On Establishment Labs

Hedge funds have recently made changes to their positions in the company. BNP Paribas Arbitrage SA increased its position in shares of Establishment Labs by 3,244.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 602 shares of the company’s stock valued at $41,000 after acquiring an additional 584 shares during the period. Baker Avenue Asset Management LP acquired a new position in shares of Establishment Labs in the 3rd quarter valued at $59,000. Global Retirement Partners LLC acquired a new position in shares of Establishment Labs in the 3rd quarter valued at $60,000. Lazard Asset Management LLC increased its position in shares of Establishment Labs by 104.5% in the 1st quarter. Lazard Asset Management LLC now owns 963 shares of the company’s stock valued at $64,000 after acquiring an additional 492 shares during the period. Finally, Deutsche Bank AG acquired a new position in shares of Establishment Labs in the 4th quarter valued at $66,000. 72.91% of the stock is owned by institutional investors and hedge funds.

Establishment Labs Stock Down 4.3 %

Establishment Labs stock opened at $50.75 on Friday. The business has a fifty day moving average of $45.80 and a two-hundred day moving average of $36.16. The company has a quick ratio of 1.67, a current ratio of 3.06 and a debt-to-equity ratio of 10.26. The firm has a market cap of $1.38 billion, a P/E ratio of -16.69 and a beta of 1.24. Establishment Labs has a twelve month low of $16.96 and a twelve month high of $77.55.

Establishment Labs (NASDAQ:ESTA – Get Free Report) last posted its earnings results on Wednesday, February 28th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.16. The company had revenue of $31.60 million during the quarter, compared to analyst estimates of $31.44 million. Establishment Labs had a negative return on equity of 357.81% and a negative net margin of 47.53%. Establishment Labs’s revenue was down 27.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.55) earnings per share. On average, analysts forecast that Establishment Labs will post -1.58 earnings per share for the current fiscal year.

About Establishment Labs

(Get Free Report

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

Further Reading